Point72 Asset Management L.P. Invests $132,000 in Evolus, Inc. (NASDAQ:EOLS)

Point72 Asset Management L.P. acquired a new stake in Evolus, Inc. (NASDAQ:EOLS) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 8,127 shares of the company’s stock, valued at approximately $132,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Quest Partners LLC acquired a new stake in shares of Evolus in the 2nd quarter valued at about $43,000. Quarry LP acquired a new stake in Evolus in the 2nd quarter valued at approximately $54,000. Dynamic Technology Lab Private Ltd bought a new stake in Evolus in the 3rd quarter valued at approximately $191,000. Profund Advisors LLC bought a new stake in Evolus in the 2nd quarter valued at approximately $130,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Evolus by 65.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,135 shares of the company’s stock worth $197,000 after acquiring an additional 4,780 shares in the last quarter. 90.69% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on EOLS. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research report on Thursday, November 7th. Barclays increased their price objective on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Friday, September 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a report on Monday, September 16th.

Evolus Price Performance

Shares of EOLS opened at $11.51 on Friday. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The company’s fifty day simple moving average is $14.48 and its 200 day simple moving average is $13.83. Evolus, Inc. has a 1-year low of $9.65 and a 1-year high of $17.82. The company has a market cap of $728.81 million, a price-to-earnings ratio of -12.65 and a beta of 1.27.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.